Biology Insights

Does IVIG Affect Blood Work? Tests & Interpretation

IVIG therapy can impact blood test accuracy. Learn how to interpret results and manage your care effectively.

By Lucy Grant

IVIG disrupts a surprisingly wide range of laboratory tests, from basic blood counts and chemistry panels to infectious disease serology and autoimmune markers. Because IVIG preparations are pooled from thousands of plasma donors, a single infusion floods your bloodstream with a concentrated mix of antibodies, proteins, and stabilizers that can mimic disease states, mask real abnormalities, or create entirely spurious results. Knowing which tests are affected and how long the interference lasts is essential for anyone receiving this therapy.

Why IVIG Interferes With So Many Tests

IVIG preparations are fractionated from the pooled plasma of several thousand donors and contain both immune antibodies and naturally occurring autoantibodies that reflect the collective immunologic experience of those donors. That means after an infusion, your blood contains antibodies to infections your donors encountered, autoantibodies your donors carried at low levels, and blood-group antibodies your donors produced. Lab assays that detect antibodies cannot distinguish between ones you made yourself and ones that arrived via IVIG. On top of the antibody cargo, the sheer protein load of an IVIG dose changes your blood’s physical and chemical properties in ways that ripple through routine chemistry panels. Some IVIG formulations also contain stabilizers like maltose or sucrose that interfere with specific assay chemistries.

Inflammatory Markers Go in Opposite Directions

One of the most counterintuitive effects of IVIG is what it does to the erythrocyte sedimentation rate, or ESR. While IVIG drives down most markers of inflammation, ESR rises sharply and stays elevated for days. In a study of children with Kawasaki disease, ESR jumped from about 13 mm/h before infusion to over 53 mm/h at 24 hours and remained near 49 mm/h a full week later. A separate study in the same patient population confirmed that ESR increased significantly at 24 hours and that this elevation persisted for at least seven days, even as C-reactive protein and other inflammation-associated proteins fell toward normal.

This divergence matters because clinicians sometimes use ESR and CRP together to track whether a treatment is working. After IVIG, CRP drops as expected while ESR does the opposite, which can create real confusion about whether the underlying disease is improving or worsening. A third study confirmed the same pattern: CRP and elevated white blood cell counts normalized after IVIG treatment, but ESR climbed from about 37 mm/h to 48 mm/h. The mechanism is straightforward: the massive bolus of immunoglobulin protein changes how red blood cells stack together, which is exactly what the ESR test measures. The inflammation may genuinely be subsiding, but the physical properties of your blood have been temporarily altered.

White Blood Cell Counts Can Drop Significantly

IVIG commonly causes a transient drop in white blood cells, and in some patients the decline is steep enough to qualify as neutropenia. In a study of adults with immune thrombocytopenic purpura, roughly half showed a decrease in white blood cell and neutrophil counts after IVIG, and about one in five of those patients developed outright neutropenia. The good news is that counts recover on their own, with a mean recovery time of about nine days and no treatment needed.

A study in patients with neurologic conditions found that white blood cells and neutrophils hit their lowest point about two days after IVIG and returned to baseline by around 14 days in most cases. The practical concern here is timing: if your blood is drawn in that two-to-seven-day window after an infusion, a low neutrophil count might prompt unnecessary alarm or even delay further treatment, when in reality the dip is a known and self-resolving effect of the therapy.

Chemistry Panels and Serum Viscosity

IVIG delivers a large amount of protein into your bloodstream very quickly. This protein load has a cascade of effects on routine lab chemistry. A study that tracked paired blood draws before and 24 hours after infusion found a statistically significant increase in total serum protein and serum viscosity, along with a decrease in serum sodium and calculated osmolality. The low sodium, however, was pseudohyponatremia, a measurement artifact caused by the extra protein displacing water in the sample. Your actual sodium levels are fine; the lab method just cannot account for the abnormal protein concentration.

Serum viscosity is a real physiological change, not just a lab artifact. In patients with various neurological conditions, serum viscosity rose after IVIG by up to 1.0 centipoise, and in several patients it exceeded the upper limit of normal, climbing as high as 2.6 centipoise. The increase correlated with serum IgG levels, which after infusion reached as high as 6,160 mg/dL against a normal upper range of about 1,560. A separate study confirmed that IVIG produced both acute and cumulative rises in plasma viscosity across a treatment course. Elevated viscosity is clinically relevant because it raises the risk of blood clots, particularly in patients who already have risk factors.

Hemolytic Anemia and the Direct Antiglobulin Test

IVIG can cause real, not artifactual, destruction of red blood cells. Because the donor pool includes people with different blood types, IVIG preparations contain anti-A and anti-B antibodies (called isohemagglutinins). When these donor antibodies bind to your red blood cells, they trigger immune-mediated hemolysis. The direct antiglobulin test, which detects antibodies stuck to red blood cells, turns positive. This is a genuine adverse effect, not just a lab oddity, and it can cause hemoglobin to drop enough to require treatment.

The risk is not equal for everyone. An analysis of hemolytic reactions found that roughly 80% of severe cases involved patients with blood group A, with very few occurring in group O patients. IVIG products with higher isohemagglutinin titers (at or above 32) had elevated reporting rates for hemolysis, especially at cumulative doses of at least 2 g/kg. If you are blood type A or B and receiving high-dose IVIG, your hemoglobin and markers of red blood cell breakdown should be monitored closely.

Infectious Disease Serology Can Be Completely Wrong

This is arguably the most dangerous category of IVIG interference because a false-positive test for HIV, hepatitis B, or syphilis can trigger invasive follow-up, psychological distress, and unnecessary treatment. The mechanism is simple: your thousands of donors have been exposed to various infections over their lifetimes, and their antibodies are now in your blood. Lab tests that look for those antibodies cannot tell the difference.

Hepatitis B is one of the best-studied examples. In a retrospective review of patients with cancer who were tested before and after IVIG, about 15% of those who were previously negative for hepatitis B core antibody became positive after receiving IVIG. None of them actually had hepatitis B; none became positive for surface antigen, and none had detectable viral DNA. A study in patients with autoimmune skin diseases confirmed the same phenomenon: all 17 patients tested had detectable anti-hepatitis B surface antibodies, and most had anti-hepatitis B core antibodies four weeks after starting IVIG.

Syphilis testing is similarly affected. Case reports document patients who tested positive on treponemal antibody tests after IVIG infusions for conditions like Guillain-Barré syndrome, with the timing clearly pointing to passive antibody transfer rather than actual infection. A review of the literature found that false-positive treponemal tests can appear as soon as six days after starting IVIG and typically take four to seven weeks to clear after IVIG is stopped, consistent with IVIG’s half-life of roughly three to four weeks.

The problem extends beyond hepatitis B and syphilis. A case report documented false-positive serologies for hepatitis B, HTLV, and other viruses after IVIG, with all results reverting to negative three weeks after the treatment was stopped. The authors noted that passive antibody transfer from IVIG is well documented but “not often considered when interpreting serologic results.” That observation captures the core problem: the interference is known in the literature, but clinicians ordering the tests often do not have IVIG on their radar as a cause of positive results.

Fungal Biomarkers

Two commonly used blood tests for invasive fungal infections are affected by IVIG. The beta-D-glucan (BDG) assay, used to screen for a broad range of fungal infections, showed false-positive results in nearly 72% of patients after IVIG infusion in a study of 131 patients. The false positives correlated with higher daily IVIG doses and larger increases in serum IgG. All BDG values returned to negative by day seven.

The galactomannan assay, used specifically to detect Aspergillus infection, is similarly compromised. Testing of IVIG samples themselves showed that all preparations tested positive for galactomannan. Among patients with positive galactomannan results within a week of IVIG, close to half were judged to be false positives. The galactomannan index declined in all false-positive patients after IVIG was completed. For immunocompromised patients who are simultaneously at risk for fungal infections and receiving IVIG, this interference creates a particularly difficult diagnostic situation. The safest approach is to delay fungal biomarker testing until at least a week after the last infusion when possible.

Blood Glucose Readings With Certain Monitors

Some IVIG formulations use maltose as a stabilizer, and maltose can cause dangerously misleading blood glucose readings on certain types of glucometers. Monitors that use glucose dehydrogenase-pyrroloquinolinequinone (GDH-PQQ) test strip chemistry cannot distinguish maltose from glucose, so they report falsely elevated blood sugar levels. Case reports have documented spuriously high glucose readings in patients receiving maltose-containing IVIG, which could lead to inappropriate insulin administration and life-threatening hypoglycemia.

The fix is straightforward: use a glucometer with glucose oxidase-based test strips, or use a laboratory glucose method that is not affected by maltose. If you are receiving a maltose-containing IVIG product, make sure the nursing staff and anyone monitoring your blood sugar are aware of this incompatibility. This is one of the few IVIG-related lab interferences that can directly cause harm through clinical action taken on a wrong result.

Kidney Function Tests

IVIG can cause real kidney injury, particularly with older sucrose-stabilized formulations, and the signal shows up on routine blood work as a rise in serum creatinine. In reported cases, creatinine elevations appeared between one and ten days after infusion and returned to baseline within two to sixty days of stopping the therapy. In a pediatric case, creatinine climbed to 4.7 mg/dL by the fourth day of treatment, a dramatic rise from normal levels. Unlike some of the other lab changes discussed here, this one is not just an artifact. The kidney injury is real, driven by the osmotic load of the IVIG product, and it requires monitoring and potentially stopping the infusion.

Autoimmune Panels and Protein Electrophoresis

Because IVIG is pooled from thousands of donors, some of whom carry low levels of autoantibodies, the infused product can make autoimmune screening tests turn positive. An analysis of IVIG preparations found that at physiological concentrations, most autoantibody tests were negative, but weak positive results for anti-neutrophil cytoplasmic antibodies (ANCA) appeared with some products. At higher, undiluted concentrations, ANCA, antinuclear antibodies (ANA), anti-cardiolipin IgG, and anti-double-stranded DNA antibodies variably tested positive. A more recent study reinforced this concern, noting that IVIG contains several autoantibodies and that their infusion can produce false-positive serology results, urging clinicians to weigh clinical symptoms more carefully before diagnosing autoimmune conditions in patients on IVIG.

Serum protein electrophoresis (SPEP), a test used to screen for blood cancers like multiple myeloma, presents another pitfall. A retrospective review of over 100,000 electrophoresis studies at Johns Hopkins found that among 348 patients confirmed to have received IVIG, about 6% showed a monoclonal spike on their SPEP, a finding that typically raises concern for a clonal plasma cell disorder. IVIG itself can produce a band that mimics a monoclonal protein because the pooled immunoglobulin migrates in a concentrated zone on the electrophoresis gel. If you are on IVIG and a protein electrophoresis result looks alarming, the timing relative to your last infusion is the first thing to check.

How Long the Interference Lasts

The duration of IVIG-related lab interference varies by test. Some changes resolve within days, while others linger for weeks. Here is a rough guide based on the available evidence:

The general principle is that anything driven by the physical presence of extra immunoglobulin in your blood will track with IgG levels as they decline. Anything driven by a biological response to the infusion, like neutrophil suppression, follows its own recovery timeline. When possible, the simplest way to avoid misinterpreting results is to schedule non-urgent blood work at least a week or two after your last infusion, and longer for serology-based tests.

Keeping Your Medical Team Informed

The recurring theme across all of these studies is not that the interference is unknown. Researchers have documented every one of these effects. The problem is that the clinician ordering a particular lab test often does not know the patient is on IVIG, or does not think to account for it. If you are seen in an emergency department, by a specialist who did not prescribe your IVIG, or at a lab that does not have your full medication history, these interferences are easy to miss. A hematologist ordering a protein electrophoresis may not know you receive monthly IVIG for a neurological condition. An infectious disease consultant seeing a positive syphilis result may not connect it to an infusion you received two weeks ago.

You can protect yourself by keeping a record of your IVIG infusion dates and product names, and mentioning it proactively whenever blood is drawn. If a test result seems inconsistent with how you actually feel, especially an unexpected positive for an infectious disease or an autoimmune marker, ask whether IVIG could explain it before agreeing to invasive follow-up. The half-life information is useful here: if a suspicious result clears within a few weeks of stopping or delaying IVIG, passive transfer rather than genuine disease was almost certainly the explanation.

Related Content

More in Tests